125 related articles for article (PubMed ID: 29363916)
1. The significance of angiogenesis for predicting optimal therapeutic response in chronic myeloid leukaemia patients.
Ćojbašić I; Mačukanović-Golubović L; Mihailović D; Vučić M; Ćojbašić Ž
Pol J Pathol; 2017; 68(3):241-251. PubMed ID: 29363916
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study.
Korkolopoulou P; Viniou N; Kavantzas N; Patsouris E; Thymara I; Pavlopoulos PM; Terpos E; Stamatopoulos K; Plata E; Anargyrou K; Androulaki A; Davaris P; Yataganas X
Leukemia; 2003 Jan; 17(1):89-97. PubMed ID: 12529665
[TBL] [Abstract][Full Text] [Related]
3. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Corrado C; Flugy AM; Taverna S; Raimondo S; Guggino G; Karmali R; De Leo G; Alessandro R
PLoS One; 2012; 7(8):e42310. PubMed ID: 22879938
[TBL] [Abstract][Full Text] [Related]
4. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
5. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
6. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
Kvasnicka HM; Thiele J; Staib P; Schmitt-Graeff A; Griesshammer M; Klose J; Engels K; Kriener S
Blood; 2004 May; 103(9):3549-51. PubMed ID: 14726401
[TBL] [Abstract][Full Text] [Related]
7. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Shih YT; Cortes JE; Kantarjian HM
Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
[TBL] [Abstract][Full Text] [Related]
8. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
Tanrikulu Simsek E; Eskazan AE; Cengiz M; Ar MC; Ekizoglu S; Salihoglu A; Gulturk E; Elverdi T; Ongoren Aydin S; Senem Demiroz A; Buyru AN; Baslar Z; Ozbek U; Ferhanoglu B; Aydin Y; Tuzuner N; Soysal T
J Clin Pathol; 2016 Sep; 69(9):810-6. PubMed ID: 26811428
[TBL] [Abstract][Full Text] [Related]
9. A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations.
Korkolopoulou P; Gribabis DA; Kavantzas N; Angelopoulou MK; Siakantaris MP; Patsouris E; Androulaki A; Thymara I; Kokoris SI; Kyrtsonis MC; Kittas C; Pangalis GA
Br J Haematol; 2003 Sep; 122(6):900-10. PubMed ID: 12956759
[TBL] [Abstract][Full Text] [Related]
10. [Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].
Kvasnicka HM; Thiele J; Staib P; Engels K; Kriener S; Schmitt-Graeff A
Pathologe; 2004 Mar; 25(2):127-34. PubMed ID: 15010998
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
Klamová H; Poláková KM; Mužík J; Ráčil Z; Záčková D; Steinerová K; Karas M; Faber E; Demečková E; Michalovičová-Sninská Z; Voglová J; Demitrovičová L; Mikušková E; Tóthová E; Chudej J; Markuljak I; Cmunt E; Moravcová J; Dvořáková D; Michalová K; Jarošová M; Sťastná MM; Cetkovský P; Dušek L; Koza V; Trněný M; Indrák K
Cancer Med; 2013 Apr; 2(2):216-25. PubMed ID: 23634289
[TBL] [Abstract][Full Text] [Related]
12. Improved prediction of clinical outcome in chronic myeloid leukemia.
Ćojbašić I; Mačukanović-Golubović L; Mihailović D; Vučić M; Lukić S
Int J Hematol; 2015 Feb; 101(2):173-83. PubMed ID: 25540066
[TBL] [Abstract][Full Text] [Related]
13. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
14. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
15. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
[TBL] [Abstract][Full Text] [Related]
17. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
18. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
19. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia.
Zhelyazkova AG; Tonchev AB; Kolova P; Ivanova L; Gercheva L
Scand J Clin Lab Invest; 2008; 68(6):492-500. PubMed ID: 18609087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
